APC resistance and third-generation oral contraceptives - Acquired resistance to activated protein C, oral contraceptives and the risk of thromboembolic disease

被引:12
作者
Gris, JC [1 ]
Jamin, C
Benifla, JL
Quere, I
Madelenat, P
Mares, P
机构
[1] Fac Pharm Montpellier, Labs Hematol, F-34060 Montpellier, France
[2] Ctr Hosp Univ, F-30029 Nimes, France
[3] Hop Bichat Claude Bernard, Serv Gynecol & Obstet, F-75018 Paris, France
关键词
acquired resistance; oral contraceptives; protein C; third-generation; thromboembolism;
D O I
10.1093/humrep/16.1.3
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Using a newly-developed technique, a severe acquired plasma resistance to activated protein C has been described in women using third-generation (rather than second-generation) oral contraceptives. The following items are discussed: (i) the technical parameters used to appreciate the effect of activated protein C induce a bias of interpretation, the mean intrinsic effect of activated protein C, in plasmas from women on second or third-generation oral contraceptives being strictly identical; (ii) there are no data available to show that this assay can indicate a thromboembolic risk in asymptomatic women on oral contraceptives; and (iii) this assay is a global and non-specific test, basically sensitive to the plasma concentrations of many coagulation factors which are increased or decreased by oestrogens and progestogens. For instance protein S, in which oral contraceptive-induced modifications account for the differential effect of oral contraceptives on Rosing's assay, but which modifications are not related to the thromboembolic risk of oral contraceptives. The androgenic potential of the progestogen may counteract the effect of oestrogens in the test, More generally, in such a complex situation in which there is a 'modification of the modification', there is no haemostasis-related test which provides a risk indicator for thrombosis. Based on testing of the plasma response to activated protein C, it is impossible to state that third-generation oral contraceptives induce a more important thromboembolic risk than oral contraceptives containing a more androgenic progestogen.
引用
收藏
页码:3 / 8
页数:6
相关论文
共 23 条
[1]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[2]   Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives [J].
Bloemenkamp, KWM ;
Rosendaal, FR ;
Helmerhorst, FM ;
Koster, T ;
Bertina, RM ;
Vandenbroucke, JP .
THROMBOSIS AND HAEMOSTASIS, 1998, 80 (03) :382-387
[3]   Acquired APC resistance and oral contraceptives: differences between two functional tests [J].
Curvers, J ;
Thomassen, MCLGD ;
Nicolaes, GAF ;
van Oerle, R ;
Hamulyak, K ;
Hemker, HC ;
Tans, G ;
Rosing, J .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (01) :88-94
[4]   FAMILIAL THROMBOPHILIA DUE TO A PREVIOUSLY UNRECOGNIZED MECHANISM CHARACTERIZED BY POOR ANTICOAGULANT RESPONSE TO ACTIVATED PROTEIN-C - PREDICTION OF A COFACTOR TO ACTIVATED PROTEIN-C [J].
DAHLBACK, B ;
CARLSSON, M ;
SVENSSON, PJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (03) :1004-1008
[5]   A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis [J].
de Visser, MCH ;
Rosendaal, FR ;
Bertina, RM .
BLOOD, 1999, 93 (04) :1271-1276
[6]  
DUCHEMIN J, 1994, THROMB HAEMOSTASIS, V71, P331
[7]  
Eichinger S, 1999, THROMB HAEMOSTASIS, V82, P1232
[8]  
FARLEY TMM, 1995, LANCET, V346, P1582
[9]   Genetic susceptibility to pregnancy-related venous thromboembolism: Roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations [J].
Grandone, E ;
Margaglione, M ;
Colaizzo, D ;
D'Andrea, G ;
Cappucci, G ;
Brancaccio, V ;
Di Minno, G .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (05) :1324-1328
[10]   Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism [J].
Heinemann, LAJ ;
Assmann, A ;
Spannagl, M ;
Schramm, W ;
Dick, A ;
Kluft, C ;
de Maat, MPM .
CONTRACEPTION, 1998, 58 (05) :321-322